Related Experiment Video
Updated: Aug 13, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Locally advanced and metastatic bladder cancer
1Department of Hematology/Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. dreicer@ccf.org
Current Treatment Options in Oncology
|June 12, 2002
Summary
Metastatic bladder cancer shows poor survival despite chemotherapy. Combining chemotherapy with targeted therapies and surgery may improve outcomes for advanced transitional cell carcinoma.
Area of Science:
- Oncology
- Urologic Oncology
- Cancer Research
Background:
- Metastatic transitional cell carcinoma of the bladder is aggressive, with median survival under 1 year.
- Current chemotherapy offers response rates of 40-80% but limited long-term survival benefits.
- Advanced bladder cancer poses challenges, especially with renal insufficiency or non-transitional cell histology.
Purpose of the Study:
- To review the current landscape of metastatic bladder cancer treatment.
- To explore the limitations of existing chemotherapy regimens.
- To highlight the potential of novel therapeutic combinations.
Main Methods:
- Review of existing literature on advanced bladder cancer treatment.
- Analysis of chemotherapy response rates and survival data.
- Comparison with treatment outcomes in extensive small cell lung cancer.
Main Results:
- Chemotherapy yields high response rates but fails to significantly extend survival in metastatic bladder cancer.
- Treatment outcomes for advanced bladder cancer are similar to extensive small cell lung cancer.
- Long-term survival remains limited despite available antineoplastic agents.
Conclusions:
- The optimal chemotherapy for advanced bladder cancer is undefined.
- Improved complete response rates and survival likely necessitate combining chemotherapy with targeted molecular therapies.
- Adjunctive surgery may be beneficial in select cases.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...